Arialys Therapeutics, Inc.
We explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.
Funding history
About Arialys Therapeutics, Inc.
How much funding has Arialys Therapeutics, Inc. raised?
Arialys Therapeutics, Inc. has raised $14.8M in total funding. The most recent round was Seed.
Where is Arialys Therapeutics, Inc. headquartered?
Arialys Therapeutics, Inc. is headquartered in La Jolla, CA.
What does Arialys Therapeutics, Inc. do?
We explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.
What problem does Arialys Therapeutics, Inc. solve?
Pathogenic autoantibodies (most commonly targeting the NMDA receptor) can attack the brain and drive severe neurological and psychiatric conditions such as encephalitis, schizophrenia, dementia, stroke, and cancer-related cognitive impairment, with treatment options currently limited.
What's Arialys Therapeutics, Inc.'s solution?
Arialys is developing precision medicines, designed using structural analysis of autoantibody-NMDAR interactions, that specifically block the effect of these pathogenic autoantibodies in the brain.
What makes Arialys Therapeutics, Inc. different?
The company describes its lead candidate ART5803 as the first precision medicine designed for autoimmune neuropsychiatric disease, and reports it has received FDA Rare Pediatric Disease Designation and FDA IND clearance for a randomized Phase 2 study.
What makes Arialys Therapeutics, Inc. notable?
Arialys Therapeutics, founded by Mitsuyuki Matsumoto, raised $58M in seed financing in 2023 with backing from Johnson & Johnson's venture arm (Johnson & Johnson Innovation/JJDC) and Alexandria Venture Investments.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.